F S&P 500
5,266.00 -18.00 (-0.34%) F Dow Jones
38,265.00 -259.00 (-0.67%) F Nasdaq
18,723.00 -79.75 (-0.42%) E-mini Russell 2000 Index Futur
2,039.30 -2.30 (-0.11%) Petróleo
79.21 -0.02 (-0.03%) Oro
2,335.00 -6.20 (-0.26%)
Pharvaris N.V. (PHVS)
Pharvaris N.V.
Emmy Noetherweg 2
Leiden 2333 BK
Netherlands
31 71 203 6410
https://pharvaris.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 83
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Berndt Axel Edvard Modig CPA, M.B.A. | Co-Founder, CEO & Executive Director | 577.82k | N/D | 1959 |
| Ms. Anna Nijdam M.Sc., R.A. | Head of Strategic Finance & Principal Accounting Officer | N/D | N/D | 1981 |
| Dr. Stefan Abele Ph.D. | Chief Technology Operations Officer | N/D | N/D | 1970 |
| Ms. Joan Schmidt J.D. | Chief Legal Officer | N/D | N/D | 1964 |
| Ms. Annick Deschoolmeester | Chief Human Resources Officer | N/D | N/D | 1973 |
| Dr. Peng Lu M.D., Ph.D. | Chief Medical Officer | N/D | N/D | 1978 |
| Dr. Anne A. Lesage Ph.D. | Chief Early Development Officer | N/D | N/D | 1961 |
| Dr. Morgan Conn Ph.D. | Chief Business Officer | N/D | N/D | 1969 |
| Mr. Wim Souverijns Ph.D. | Chief Commercial Officer | N/D | N/D | 1971 |
| Mr. David W. Nassif J.D. | Chief Financial Officer | N/D | N/D | 1954 |
Descripción
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.
Gestión corporativa
La calificación ISS Governance QuickScore de Pharvaris N.V. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
